Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$173.00 USD

173.00
994,173

-0.27 (-0.16%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $172.98 -0.02 (-0.01%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Envista Stock Climbs on Q3 Earnings and Revenue Beat, Margins Crash

by Zacks Equity Research

NVST delivers better-than-expected top and bottom-line performance in the third quarter of 2024.

Zacks Equity Research

Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market

by Zacks Equity Research

The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.

Zacks Equity Research

MMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin

by Zacks Equity Research

Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.

Zacks Equity Research

Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance

by Zacks Equity Research

SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.

Zacks Equity Research

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued momentum across its Diagnostics & Spatial Biology segment.

Zacks Equity Research

DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

DVA's robust Dialysis patient service revenues drives its third-quarter performance.

Zacks Equity Research

ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed

by Zacks Equity Research

Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024.

Zacks Equity Research

ECL Q3 Earnings Surpass Estimates, Revenues Miss, Margins Rise

by Zacks Equity Research

Ecolab's robust performance across the majority of its segments drives its third-quarter sales.

Zacks Equity Research

AMIS Stock Surges After RF Ablation Trial Unveils Positive Results

by Zacks Equity Research

Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.

Zacks Equity Research

Here's Why You Should Add Veeva Stock in Your Portfolio Now

by Zacks Equity Research

VEEV's robust product portfolio raises optimism about the stock. However, escalating costs are concerning.

Zacks Equity Research

Avantor's Stock Declines Despite Q3 Earnings Beat, Margins Down

by Zacks Equity Research

Despite AVTR's continued stability in the Education and Advanced Technology end markets, it reports an overall soft third-quarter performance.

Zacks Equity Research

ALGN Stock Rise on the Release of Invisalign Smile Architect Software

by Zacks Equity Research

Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.

Zacks Equity Research

Integer Holdings Q3 Earnings Surpass Estimates, Revenues Up Y/Y

by Zacks Equity Research

ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.

Zacks Equity Research

DexCom Q3 Earnings Beat Estimates on Sensor Growth, Stock Rises

by Zacks Equity Research

DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

Debanjana Dey headshot

DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?

by Debanjana Dey

Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.

Zacks Equity Research

Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand

by Zacks Equity Research

RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

Zacks Equity Research

ALUR Stock Declines Despite Submitting PMA for Allurion Balloon

by Zacks Equity Research

Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.

Zacks Equity Research

Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare

by Zacks Equity Research

Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare have been highlighted in this Industry Outlook article.

Zacks Equity Research

ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

by Zacks Equity Research

AngioDynamics announces the receipt of CPT Category I code for IRE technology.

Zacks Equity Research

Reasons to Retain Ecolab Stock in Your Portfolio for Now

by Zacks Equity Research

ECL's focus on cost-efficiency programs raises optimism about the stock.

Zacks Equity Research

DGX or PNTG: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DGX vs. PNTG: Which Stock Is the Better Value Option?

Debanjana Dey headshot

4 Stocks to Buy in an Evolving Outpatient Home Health Industry

by Debanjana Dey

Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.

Zacks Equity Research

Revvity Shares Decline Despite Launch of Transcribe AI Solution

by Zacks Equity Research

RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.

Zacks Equity Research

Thermo Fisher Q3 Earnings Top Estimates, Revenues Miss, Stock Dips

by Zacks Equity Research

In the third quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.